Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial

Anders Widmark, Adalsteinn Gunnlaugsson, L. Beckman, +16

The Lancet

Surgical OncologyRadiation TherapyMedicineProstatic DiseaseOncology +6

2-weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial

Pirkko‐Liisa Kellokumpu‐Lehtinen, Ulrika Harmenberg, Timo Joensuu, +17

The Lancet Oncology

UrologyOncologyGenitourinary CancerClinical TrialsPharmacotherapy +3

Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial

Per Fransson, Per Nilsson, Adalsteinn Gunnlaugsson, +15

The Lancet Oncology

Radiation MedicineRadiation TherapyMedicineProstatic DiseaseOncology +6

Patient-controlled dose regimen of methadone for chronic cancer pain.

Juliette Säwe, Jacob J. Hansen, Claes Ginman, +5

BMJ

Pain TherapySubstance AbuseHealth SciencesPain MedicineAddiction +12

Adipose Tissue Concentrations of Persistent Organic Pollutants and the Risk of Prostate Cancer

Lennart Hardell, Swen‐Olof Andersson, Michael Carlberg, +5

Journal of Occupational and Environmental Medicine

Weekly Docetaxel and Prednisolone versus Prednisolone Alone in Androgen-Independent Prostate Cancer: A Randomized Phase II Study

Sophie D. Fosså, Anne-Birgitte Jacobsen, Claes Ginman, +7

European Urology

UrologyGenitourinary CancerMedicineWeekly DocetaxelAndrogen-independent Prostate Cancer +4

Palliation of Bone Pain in Prostate Cancer Using Chemotherapy and Strontium-89. A Randomized Phase II Study

Sten Nilsson, Peter Strang, Claes Ginman, +6

Journal of Pain and Symptom Management

Extreme Hypofractionation versus Conventionally Fractionated Radiotherapy for Intermediate Risk Prostate Cancer: Early Toxicity Results from the Scandinavian Randomized Phase III Trial “HYPO-RT-PC”

Anders Widmark, Adalsteinn Gunnlaugsson, L. Beckman, +11

International Journal of Radiation Oncology*Biology*Physics

Radiation MedicineRadiation TherapyMedicineProstatic DiseaseOncology +5

Preoperative Irradiation of Primarily Non-Resectable Adenocarcinoma of the Rectum and Rectosigmoid

Lars Påhlman, Bengt Glimelius, Claes Ginman, +2

Acta Radiologica Oncology

Adaptive RadiotherapyPrimarily Non-resectable AdenocarcinomaSurgical OncologyRadiation TherapyColorectal Surgery +9

Docetaxel Versus Surveillance After Radical Radiotherapy for Intermediate- or High-risk Prostate Cancer—Results from the Prospective, Randomised, Open-label Phase III SPCG-13 Trial

Pirkko‐Liisa Kellokumpu‐Lehtinen, Marie Hjälm-Eriksson, Camilla Thellenberg‐Karlsson, +7

European Urology

High-risk Prostate Cancer—resultsUrologyRadiation MedicineRadiation TherapyMedicine +5